S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
S&P 500   3,852.36
DOW   32,920.46
QQQ   290.27
Mullen Automotive On Hiring Spree, What Could That Mean? 
The Next Big Crisis Is Here (Ad)
What You Need to Know About Annuity Withdrawals
SoFi Technologies Smashes Earnings but Beware the Fed Decision
Is This The End of Capitalism? (Ad)
Why Extreme Networks is a Recession-Proof Technology Play
Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
Is This The End of Capitalism? (Ad)
Grab Shares Are Suddenly On Track To Double
Buying The Dip In Colgate-Palmolive 
NASDAQ:AGEN

Agenus - AGEN Stock Forecast, Price & News

$2.55
-0.08 (-3.04%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.55
$2.68
50-Day Range
$2.17
$3.04
52-Week Range
$1.25
$3.37
Volume
3.45 million shs
Average Volume
4.23 million shs
Market Capitalization
$777.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.83

Agenus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
246.1% Upside
$8.83 Price Target
Short Interest
Bearish
6.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.36mentions of Agenus in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

604th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

95th out of 170 stocks


AGEN stock logo

About Agenus (NASDAQ:AGEN) Stock

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Stock News Headlines

Agenus to Participate in February Investor Conferences
Agenus' Updated Data Confirms Long-Term Potential Value
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Agenus (NASDAQ:AGEN) Shares Up 3.3%
2 Momentum Trades Showing Worst to First Action
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Agenus: Perpetually Getting There
Why Shares of Agenus Rose 12.5% on Friday
Agenus (AGEN) Q3 2022 Earnings Call Transcript
Agenus (AGEN) to Report Q3 Earnings: What's in the Cards?
Agenus (AGEN) Gains But Lags Market: What You Should Know
See More Headlines
Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Company Calendar

Last Earnings
11/08/2022
Today
1/30/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
441
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.83
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+246.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-23,930,000.00
Net Margins
-249.35%
Pretax Margin
-249.35%

Debt

Sales & Book Value

Annual Sales
$295.67 million
Book Value
$0.19 per share

Miscellaneous

Free Float
290,181,000
Market Cap
$777.27 million
Optionable
Optionable
Beta
1.33

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 70)
    Founder, Exec. Chairman & CEO
    Comp: $1.28M
  • Ms. Christine M. Klaskin (Age 57)
    VP of Fin., Principal Financial Officer & Principal Accounting Officer
    Comp: $360.51k
  • Dr. Steven J. O'Day M.D. (Age 61)
    Ph.D., Chief Medical Officer
    Comp: $1.44M
  • Dr. Jennifer S. Buell Ph.D. (Age 48)
    Pres & CEO of MiNK Therapeutics
    Comp: $917.25k
  • Craig Winter
    Chief Information Officer
  • Regina Grebla Ph.D.
    VP of Investor Relations & Communications
  • Ms. Robin E. Abrams J.D. (Age 59)
    Chief Legal Officer
  • Ms. Tracy Mazza Clemente
    Chief People Officer
  • John Castle
    Head of Translational Medicine & Bioinformatics
  • Ms. Julie DeSander
    Chief Bus. Officer













AGEN Stock - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price forecast for 2023?

3 analysts have issued twelve-month price objectives for Agenus' shares. Their AGEN share price forecasts range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $8.83 in the next year. This suggests a possible upside of 246.1% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How have AGEN shares performed in 2023?

Agenus' stock was trading at $2.40 on January 1st, 2023. Since then, AGEN stock has increased by 6.3% and is now trading at $2.55.
View the best growth stocks for 2023 here
.

When is Agenus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AGEN earnings forecast
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) posted its quarterly earnings data on Tuesday, November, 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. The biotechnology company had revenue of $22.77 million for the quarter, compared to analyst estimates of $19.86 million. Agenus had a negative net margin of 249.35% and a negative trailing twelve-month return on equity of 1,159.04%.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?
What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by many different institutional and retail investors. Top institutional investors include Lindbrook Capital LLC (0.44%), Strs Ohio (0.08%), Allspring Global Investments Holdings LLC (0.02%), Lynch & Associates IN (0.01%), Calamos Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends
.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $2.55.

How much money does Agenus make?

Agenus (NASDAQ:AGEN) has a market capitalization of $777.27 million and generates $295.67 million in revenue each year. The biotechnology company earns $-23,930,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Agenus have?

The company employs 441 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.

This page (NASDAQ:AGEN) was last updated on 1/31/2023 by MarketBeat.com Staff